Elixirgen Therapeutics is a pioneering brand that is revolutionizing the field of RNA therapeutics. They specialize in harnessing the power of controllable self-replicating RNA (c-srRNA™) technology to develop innovative therapies for a wide range of diseases, including rare diseases, aging-related disorders, and cancer. At the heart of their breakthrough treatments is the ZSCAN4 gene, which was originally discovered by their Chief Scientific Officer, Dr.

Minoru Ko, as part of the Human Genome Project. This unique gene plays a crucial role in various genomic functions, such as telomere extension and karyotype correction, enabling the restoration of the developmental potential of stem cells. Elixirgen Therapeutics has assembled a world-class team dedicated to unraveling the full potential of the ZSCAN4 gene and creating life-changing therapies for patients in need.

They are currently studying the therapeutic benefits of their ZSCAN4-based stem cell therapy platform, EXG-34217, in telomere biology disorders. In the future, they plan to combine the power of their c-srRNA platform with the ZSCAN4 platform to address additional cell therapy indications. With their cutting-edge technology and commitment to innovation, Elixirgen Therapeutics is at the forefront of next-generation RNA therapeutics, bringing hope to patients worldwide